Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a45ceb22dcdf3488

Jump to content

// Workers AI · dad joke modeWhat did de novo say to the pill? "You're a novel friend

From Wikipedia, the free encyclopedia

De novo drug design is a specialized approach within drug discovery, focusing on the creation of molecular structures with drug-like properties that are distinct from existing therapeutic agents. Unlike traditional drug development, which iteratively modifies known molecules, de novo methods generate novel structures from scratch, leveraging either rational or random approaches.[1][2][3] This technique often utilizes detailed information about the target structure (typically a protein) and known binders to generate new patterns of binding.[4]

See also

[edit]

References

[edit]
  1. ↑ Moon, Joseph B.; Howe, W.Jeffrey (January 1990). "3D database searching and de novo construction methods in molecular design". Tetrahedron Computer Methodology. 3 (6): 697–711. doi:10.1016/0898-5529(90)90168-8.
  2. ↑ Martinelli, Dominic D. (June 2022). "Generative machine learning for de novo drug discovery: A systematic review". Computers in Biology and Medicine. 145 105403. doi:10.1016/j.compbiomed.2022.105403. PMID 35339849.
  3. ↑ Crucitti, Davide; Pérez Míguez, Carlos; Díaz Arias, José Ángel; Fernandez Prada, Diego Beltrán; Mosquera Orgueira, Adrián (25 January 2024). "De novo drug design through artificial intelligence: an introduction". Frontiers in Hematology. 3 1305741. doi:10.3389/frhem.2024.1305741.
  4. ↑ Tang, Yidan; Moretti, Rocco; Meiler, Jens (25 March 2024). "Recent Advances in Automated Structure-Based De Novo Drug Design". Journal of Chemical Information and Modeling. 64 (6): 1794–1805. doi:10.1021/acs.jcim.4c00247. PMC 10966644. PMID 38485516.